A first-in-human Phase 1 single-ascending dose study of GPR84 antagonist evaluating the safety and tolerability in healthy volunteers
Latest Information Update: 24 May 2021
At a glance
- Drugs PBI 4425 (Primary)
- Indications Acute lung injury; Diabetic nephropathies; Hepatic fibrosis; Pulmonary fibrosis; Scleroderma
- Focus Adverse reactions; First in man
- 24 May 2021 New trial record
- 17 May 2021 According to a Liminal BioSciences media release, the company plans to initiate a pre-clinical IND enabling program to support this study.